Intravenous ganciclovir is indicated for the treatment of CMV retinitis in immunocompromised individuals, including those with AIDS, and for the prevention of CMV infection in organ transplant recipients. Oral gan-ciclovir is less effective than the intravenous preparation but carries a lower risk of adverse effects. It is approved for the prevention of CMV disease in immunocompromised individuals and transplant patients. It is also indicated as a maintenance therapy for treatment of CMV retinitis in AIDS and other immunocom-promised conditions. Ganciclovir is also available as an intravitreal implant (Vitrasert) for the treatment of CMV retinitis in AIDS patients.
Oral valganciclovir is comparable to intravenous ganciclovir for the treatment and suppression of CMV retinitis in AIDS patients.
Was this article helpful?
This guide will help millions of people understand this condition so that they can take control of their lives and make informed decisions. The ebook covers information on a vast number of different types of neuropathy. In addition, it will be a useful resource for their families, caregivers, and health care providers.